Beam Therapeutics
开盘价
市值
最高价
最低价
收盘价
成交量
市盈率
股息率
Beam Therapeutics简介
BEAM治疗公司开发用于治疗人类疾病的DNA碱基编辑技术并将其商业化。其许可的技术平台，其中包括使用基本编辑技术和相关技术，以扩大基本编辑的范围。该公司由David R.Liu、冯章、Alexis Komor、Nicole Gaudelli和J.Keith Joung于2017年1月25日创立，总部位于马萨诸塞州剑桥市。
如何购买 Beam Therapeutics (BEAM)
登录
1分钟开户
仅需1分钟即可完成账户申请和验证。整个过程完全自助，支持 RockFlow App 和网页端操作。
充值资金
账户验证完成后，您可以使用首选的支付方式向账户充值。
购买 BEAM
通过 RockFlow App 或网页端搜索 BEAM，输入您想要投资的金额，然后点击确认即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.